Printer Friendly
The Free Library
5,672,723 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Stellar Pharmaceuticals Schedules Fourth Quarter and Year End Financial Results and Conference Call.


LONDON -- Stellar Pharmaceuticals Inc., (TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension
 VENTURE:SLX SLX Student Loan Xpress
SLX Smartlet Xml
SLX Secure Links
SLX Super Luxe
)(OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that it plans to release its 2005 fourth quarter and year-end financial results prior to the opening of the stock market on Wednesday, March 29, 2006. Management will conduct a conference call that morning at 10:00 a.m. Eastern Time to discuss these results. Interested parties may participate in the call by dialing 888-789-0150 (in the United States) or 416-695-6622 (in Canada) approximately 10 minutes before the call is scheduled to begin and ask to be connected to the Stellar Pharmaceuticals Conference Call. A recorded replay of the call will be available until 11:59 pm Eastern Time on Wednesday, April 5, 2006. Listeners may dial 888-509-0081 (in the United States) or 416-695-5275 (in Canada) for the replay.

The call will also be simultaneously broadcast over the Internet. Those interested in listening to the live web cast may do so by going to the Company's website at www.stellarpharma.com or by going to www.ccnmatthews.com/StellarPharmaceuticalsQ4. Web participants are encouraged to go to either website at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The online archive will be available immediately after the live call and continue for approximately 30 days.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc(R), for the treatment of osteoarthritis; and Uracyst(R) and the Uracyst(R) Test Kit, its patented technology for the diagnosis and treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Stellar also has an in-licensing agreement for NMP NMP New Millennium Program (NASA)
NMP National Military Park (National Park Service)
NMP N-Methylpyrrolidone
NMP Network Management Protocol
NMP Not My Problem
22(R) BladderChek(R), a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence ob·so·les·cent  
adj.
1. Being in the process of passing out of use or usefulness; becoming obsolete.

2. Biology Gradually disappearing; imperfectly or only slightly developed.
; general economic conditions; and other risks detailed from time to time in the Company's filings.

The TSX Venture Exchange TSX Venture Exchange

Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors.
 has not reviewed and does not accept resp onsibility for the adequacy or accuracy of this release.

Stellar Pharmaceuticals Inc. (TSX VENTURE:SLX) (OTC Bulletin Board OTC Bulletin Board

An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system.
:SLXCF)
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 22, 2006
Words:439
Previous Article:New 4-Hour California Annuity Training Course Now Available Through WebCE; New Course Fulfills the Renewal Requirement for All Insurance Agents...
Next Article:Vcall, Perry S. Marshall & Associates and Must See-Webinars Host Webinar on ''Marketing Success with Google AdWords''.



Related Articles
Stellar Pharmaceuticals Schedules Fourth Quarter And Year-End Financial Results And Conference Call.
Stellar Pharmaceuticals Announces 2004 Financial Results.
Stellar Pharmaceuticals Schedules First Quarter Financial Results And Conference Call.
Stellar Pharmaceuticals Inc. Announces 2005 First Quarter Financial Results.
Stellar Pharmaceuticals Schedules Second Quarter Financial Results and Conference Call.
Stellar Pharmaceuticals Announces 2005 Second Quarter Financial Results.
Stellar Pharmaceuticals Schedules Third Quarter Financial Results And Conference Call.
Stellar Pharmaceuticals Reports Third Quarter Financial Results.
Stellar Pharmaceuticals Reschedules Fourth Quarter and Year End Financial Results and Conference Call.
Stellar Pharmaceuticals Announces 2005 Fourth Quarter and Year End Financial Results.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles